LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

Home・Stock List・Alkermes PLC

Alkermes PLC

Open

Sector Healthcare

27.79 0.29

Buy Sell

Overview

Share price change

24h

Current

Min

27.7

Max

28.86

Key metrics
By Trading Economics
Income	-76M 37M
Sales	-27M 350M
P/E Sector Avg	8.85 79.786
EPS	0.43
Profit margin	10.51
EBITDA	-31M 61M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+35.8 upside

Dividends
By Dow Jones
Next Earnings	23 Oct 2024

Market Stats
By TradingEconomics
Market Cap	-170M 3.9B
Previous open	27.5
Previous close	27.79

News Sentiment

By Acuity

17%

83%

21 / 369 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

24.6 / N/A Support & Resistance

Alkermes PLC Chart

Related News

14 Dec 2023, 11:06 UTC

Acquisitions, Mergers, Takeovers

Alkermes Athlone Facility Has About 400 Employees >ALKS

14 Dec 2023, 11:06 UTC

Acquisitions, Mergers, Takeovers

Alkermes to Get Cash Payment of $92.5 Million for Facility, Related Assets >ALKS

Peer Comparison

Price change

Alkermes PLC Forecast

Price Target

By TipRanks

35.8% upside

12 Months Forecast

Average 36 USD 35.8%

High 50 USD

Low 28 USD

Based on 12 Wall Street analysts offering 12 month price targets forAlkermes PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Alkermes PLC - Dist in the past 3 months.

Technical Score

By Trading Central

24.6 / N/ASupport & Resistance

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

21 / 369 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.